

NEXT-GENERATION IMMUNOMEDICINES

OCTOBER 2019

Forward-Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "next," "near-term," "future" and similar expressions, as well as other words and expressions referencing future events, conditions, or circumstances, are intended to identify forward-looking statements. Examples of forward-looking statements in this presentation may include, among others, statements regarding: (i) the timing, progress and results of our preclinical and clinical trials; (ii) the timing or likelihood of regulatory filings for our product candidates; (iii) our manufacturing capabilities and strategy; (iv) the potential benefits and activity of our product candidates; (v) our expectations regarding the nature of the biological pathways we are studying; (vi) our expectations regarding our FIND-IO platform; and (vii) the potential benefits of our relationships with Dr. Lieping Chen, Yale University and Eli Lilly and Company.

Various factors could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. For further discussion of these and other factors that could affect the outcome of our forward-looking statements, see our filings with the Securities and Exchange Commission, including in "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Risk Factors section and throughout NextCure's Form 10-Q filed with the SEC on August 12, 2019. Except as otherwise indicated, this presentation speaks as of the date indicated herein. Except as required by law, we assume no obligation to update any forward-looking statements, even if new information becomes available in the future. The information in this presentation is not complete and may be changed.

NEXTCURE HIGHLIGHTS

Pipeline of Immuno- medicines	 NC318: Phase 1 data to be presented November 9th at SITC* 2019 NC410 (LAIR-1): IND expected Q1 2020 Additional research and development programs Manufacturing: dedicated, state-of-the-art facility
Platform for Novel Target Discovery	 FIND-IO functional screening discovery engine Oncology partnership with Lilly: \$40M upfront and equity Expanding into autoimmune diseases

Proven Abilities

- Experienced Management team
- Scientific founder Dr. Lieping Chen: discovered PD-L1 & other key targets
- Strong balance sheet to deliver on objectives

*Title "Single agent anti-tumor activity in PD-1 refractory NSCLC: phase 1 data from the first-in-human trial of NC318, a Siglec-15-targeted antibody"

THE UNMET NEEDS OF CANCER PATIENTS ARE SIGNIFICANT

NON-RESPONDERS RAPID PROGRESSION LIMITED TREATMENTS



We Need New Solutions



COMMITTED TO DISCOVERING & DEVELOPING NOVEL, FIRST-IN-CLASS IMMUNOMEDICINES TO IMPROVE LIVES




Focused on Cancer Patients Not Adequately Addressed Today





EXPANDING TARGETS BEYOND T CELLS





EXPERIENCED TEAM WITH STRONG TRACK RECORD

HISTORY AND SUCCESS OF WORKING TOGETHER

Michael Richman CEO		MACROGENICS	MedImmune	CHIRON
Timothy Mayer, PhD COO	MACROGENICS	BANNER & WITCOFF, LTD.	💩 invitrogen	life
Steve Cobourn, CPA CFO	ACCÍNEX	Otsuka		
Kevin N Heller, MD CMO	Incyte	AstraZeneca	Bristol-Myers Squibb	With the second
Sol Langermann, PhD CSO		Reference PharmAthene	MedImmune	
Jim Bingham, PhD CDO		Lonza	Human Genome Sciences	MedImmune
Linda Liu, PhD SVP, Research		Max©yte	OSIRIS 🙃	St. Jude Childrens Research Hospital
Sebastien Maloveste, PhD VP, Business Development	🌔 G e n V e c			
Dallas Flies, PhD VP, Discovery Research	UNM	Yale University	JOHNS HOPKINS	mayo



WORLD-RENOWNED SCIENTIFIC FOUNDER AND KEY COLLABORATION

YALE COLLABORATION

NATURE MEDICINE PUBLICATION

LIEPING CHEN, MD, PhD

Discovered multiple key immune pathways, including PD-L1





WORLD-RENOWNED INSTITUTION

Sponsored research, clinical samples, cell lines & models

TEAM OF COLLABORATORS

Roy Herbst, MD, PhD David Rimm, MD, PhD Mario Sznol, MD

medicine

ARTICLES https://doi.org/10.1038/s41591-019-0374-x

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Jun Wang^{1,5}, Jingwei Sun^{1,5}, Linda N. Liu², Dallas B. Flies², Xinxin Nie¹, Maria Toki³, Jianping Zhang¹, Chang Song², Melissa Zarr², Xu Zhou¹, Xue Han¹, Kristina A. Archer², Thomas O'Neill², Roy S. Herbst⁴, Agedi N. Boto^{1,3}, Miguel F. Sanmamed¹, Solomon Langermann², David L. Rimm¹, and Lieping Chen^{1,4*}



NEXTCURE HAS DELIVERED ROBUST PRODUCT PIPELINE IN LESS THAN 3 YEARS

PROGRAMS	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	NEXT MILESTONE	WORLDWIDE RIGHTS
PRODUCT	F CANDIDATES							
NC318 (S15)	Tumors and macrophages	ONCOLO	DGY				Phase 1 complete in Q4 2019	Next© ure
NC410 (LAIR-1)	Dendritic & T cells	ONCOLO	DGY				IND filing in Q1 2020	Next© ure
DISCOVE	RY AND RESEA	RCH PROGI	RAMS					
Multiple Programs	Immune cells						First IND filing in early 2021	Next© ure
FIND-IO Platform	Multiple cell types						First IND filing in late 2022	Lilly Next©ure

NC318 humanized monoclonal antibody



Phase 1/2 Clinical Trial

TARGET

Siglec-15 ("S15")

CELL TYPES

Tumors & macrophages

MOA

Designed to block S15-induced immunosuppression

INDICATIONS

Advanced or metastatic solid tumors, which could include ovarian, NSCLC, and head & neck cancers

S15 AS A TARGET

EXPRESSION


FUNCTION


Potently Suppresses

T Cell Function


NON-RESPONDERS









Generally Non-Overlapping with PD-L1 Expression



S15 IS HIGHLY IMMUNOSUPPRESSIVE IN THE TME OF MULTIPLE TUMOR TYPES



NC318 IS DESIGNED TO BLOCK IMMUNOSUPPRESSIVE ACTIVITY INDUCED BY S15





NC318: A POTENTIAL TREATMENT OPTION FOR PD-1/PD-L1 NON-RESPONDERS

S15 AND PD-L1 EXPRESSION GENERALLY DO NOT OVERLAP IN NSCLC TUMORS*

POTENTIAL NEW TREATMENT OPTIONS FOR PD-1/PD-L1 NON-RESPONDERS


PD-1/PD-L1 Treatment





S15 IS CLINICALLY AND FUNCTIONALLY RELEVANT

Clinical Relevance



S15


- Increased expression on tumor cells and immunosuppressive macrophages in multiple cancer types
- Minimal expression in normal tissues

Functional Relevance




- S15-deficient mice showed
 - Enhanced antigen-specific T cell responses *in vivo*
 - Delayed tumor progression
 - Increase in survival

NC318 RESTORED IMMUNE FUNCTION IN VITRO



NC318* HAS SHOWN <u>MONOTHERAPY</u> ACTIVITY IN A NUMBER OF ANIMAL MODELS




*Murine surrogate is 5G12



NC318 MONOTHERAPY TRIAL UNDERWAY DESIGNED FOR RAPID PROOF-OF-CONCEPT

PHASE 1	PHASE 2			
 Opened in 4Q 2018; Complete in 4Q 2019 Dose-escalation¹ Safety, tolerability, and biomarker readouts Advanced or metastatic solid tumors 	 Open in 1Q 2020; Complete in 4Q 2020 Efficacy assessment Tumor types shown to have elevated S15 expression, including NSCLC, ovarian, and head & neck 			



(1) Dose escalation evaluates 6 dose cohorts (8 mg - 800 mg or approximately 0.1 - 10 mg/kg) administered every 2 weeks

(2) In Phase 2 portion of trial

NC318 PHASE 1 TRIAL STATUS AS OF MARCH 31, 2019

ENROLLMENT

- 21 subjects dosed
- 4th dose cohort open
- 10 different tumor types
- Recruitment on schedule

SAFETY

- No dose limiting toxicities or drug-related SAEs
- 1 transient elevation of amylase (grade 3) and lipase (grade 4) that was deemed probably related to NC318⁽¹⁾
- Possibly NC318-related AEs limited to transient asymptomatic lab findings or grade 1 events

RESPONSES

- Evaluations every 8 weeks
- 1 confirmed partial response
- 6 stable disease
- 6 progressive disease
- 8 subjects not yet evaluated

• Angeles Clinic

• MSKCC

Next Oncology

y •NYU

• Yale University

(1) The patient was asymptomatic and both elevations resolved without any interventions within 72 hours

NC318 DESIGNED TO RESTORE IMMUNE FUNCTION IN A HIGHLY SUPPRESSIVE TUMOR MICROENVIRONMENT



- Relieved S15-mediated inhibition of T cells
- Increased IFN-γ production
- Decreased inflammatory cytokines
- First-in-Human trial initiated in October 2018
- Complete Phase 1 and report data at SITC 2019
- Complete Phase 2 in Q4 2020



Lot No: DP-18-0001-01 Name: NC318 Protocol No: NC318-01 Mg-Limited by Federal (orling) aw to investigational use Mg/vial, 60 mg/mL in 5.0m Store frozen -20°C to -50°C IOT SHAKE OR DROP THEM NextCure, Inc.

NC410 DECOY HUMAN FUSION PROTEIN TARGETING THE TME



IND Filing Expected Q1 2020

TARGET

Leukocyte-Associated Immunoglobulinlike Receptor-1 (LAIR-1)

CELL TYPES

Dendritic cells and T cells

MOA

Promotes T cell function and dendritic cell activity

INDICATIONS

Advanced or metastatic solid tumors



LAIR-1 & LAIR-2 FUNCTIONAL RELATIONSHIP

LAIR & LIGANDS

LAIR-1 and LAIR-2 bind collagen and C1q


LAIR-1


Ligands are expressed in response to inflammation & inhibit immune function

Tissue Damage Inhibited T cell Inhibited Dendritic Cells

LAIR-2


LAIR-2 modulates LAIR-1 mediated inhibition






NC410 IS DESIGNED TO PREVENT IMMUNE SUPPRESSION CAUSED BY LAIR-1

NC410 is a Fusion Protein of LAIR-2 and a Decoy for LAIR-1




NC410 Promotes T Cell Function and Dendritic Cell Activation

NC410 ENHANCED T CELL EXPANSION AND RELIEVED IMMUNOSUPPRESSION




DECREASED Tumor Volume



Human PBMCs in mice: CD8+ T cell activity decreased tumor volume

NC410 PROMOTED IMMUNE CELL ACTIVATION IN THE PRESENCE OF COLLAGEN AND C1Q






NC410 SUMMARY

Based on normal immune regulatory mechanism

Promoted T cell function and dendritic cell activity in preclinical studies

Designed to alleviate tumor-mediated immunosuppression


- IND-enabling tox studies complete
- ☑ cGMP manufacturing
- □ IND filing expected Q1 2020






FINDING SOLUTIONS WITH A POWERFUL DISCOVERY ENGINE


Functional, Integrated, NextCure Discovery in Immuno-Oncology




FIND-IO SCREENING METHODOLOGY




JURKAT "T CELL LINE" SCREENING AND VALIDATING FIND-IO HITS



LILLY - NEXTCURE PARTNERSHIP TO VALIDATE PLATFORM AND APPROACH



DIVERSIFICATION BEYOND ONCOLOGY





ANTICIPATED NEAR-TERM MILESTONES







Committed to Addressing the Unmet Needs of Cancer Patients With New Solutions

FOCUSED Approach PROVEN Momentum INNOVATIVE Platform

EXPERIENCED Team FUTURE Deliverables

